Hopp til innhold
NHI.no
Annonse

Allergi mot grønnsaker og frukt: Soyabønner

Innhold i artikkelen

Soyaprodukter er mye brukt innen matvareindustrien, særlig for å gi maten riktig konsistens, sørge for at de ulike ingrendiensene blandes godt med hverandre (emulgator) og protein fylningsmiddel. Soyabønner er også en viktig kilde til raffinert olje, men disse inneholder sannsynligvis ikke store mengder med allergene proteiner. Symptomer på soyabønneallergi varierer fra milde til livstruende. Soyabønner blir i likhet med peanøtter regnet som en av de viktigste matallergenene, og de er samtidig regnet som et av de mest utfordrende å unngå. Dette er fordi det blir brukt i så mange bearbeidede matvarer.

Annonse

Kostråd

Sjekklister

Om matvareallergi og matvareintoleranse

Dette dokumentet er basert på det profesjonelle dokumentet Allergi mot grønnsaker og frukt . Referanselisten for dette dokumentet vises nedenfor

  1. Nowak-Węgrzyn A. Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome). UpToDate, last updated July 17, 2012. UpToDate
  2. Lack GT, Fox D, Northstone K, Golding J. Factors associated with the development of peanut allergy in childhood. N Engl J Med 2003; 348: 977-85. PubMed
  3. Asarnoj A, Movérare R, Östblom E, et al. IgE to peanut allergen components: relation to peanut symptoms and pollen sensitization in 8-year-olds. Allergy 2010; 65: 1189-95. doi:10.1111/j.1398-9995.2010.02334.x DOI
  4. Maloney JM, Rudengren M, Ahlstedt S, et al. The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy. J Allergy Clin Immunol 2008; 122:145. PMID: 18502490 PubMed
  5. Toit GD, Roberts G, Sayre PH, et al. Randomized trial of peanut comsumption infants at risk for peanut allergy. N Engl J Med 2015; 372: 803-13. pmid: 25705822 PubMed
  6. Toit GD, Sayre PH, Roberts G, et al. Effevt of avoidance on peanut allergy after early peanut consumption. N Engl J Med 2016. doi:10.1056/NEJMoa1514209 DOI
  7. Greenhawt M. The Learning Early About Peanut Allergy Study: The Benefits of Early Peanut Introduction, and a New Horizon in Fighting the Food Allergy Epidemic. Pediatr Clin North Am. 2015 Dec;62(6):1509-21. doi: 10.1016/j.pcl.2015.07.010.
  8. Clark AT, Islam S, King Y, et al. Successful oral tolerance inductionin severe peanutallergy. Allergy 2009; 64: 1218-20. PubMed
  9. Jones SM, Pons L, Roberts JL, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009; 124: 292-300. PubMed
  10. Anagnostou K, Islam S, King Y, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 2014. doi:10.1016/S0140-6736(13)62301-6 DOI
  11. The PALISADE Group of Clinical Investigator: Vickery BP, Vereda A, Casale TB, et al. AR101 Oral Immunotherapy for Peanut Allergy. N Engl J Med 2018. pmid:30449234 PubMed
  12. Jones SM, Kim EH, Nadeau KC, et al. Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. Lancet 2022; 399: 359-371. doi:10.1016/S0140-6736(21)02390-4 DOI
  13. Chinthrajah RS, Purington N, Andorf S, et al. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2019. pmid:31522849 PubMed
  14. Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet 2019; 399: 2222-32. pmid:31030987 PubMed
  15. FDA. FDA approves first drug for treatment of peanut allergy for children. Jan. 31, 2020. www.fda.gov
  16. Toit GD, Browvn KR, Vereda A, et al. Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age. NEJM Evid 2023. doi:10.1056/EVIDoa2300145 DOI
  17. Fleischer DM, Greenhawt M, Sussman G, et al. Effect of epicutaneous immunotherapy vs placebo on reaction to peanut ingestion among children with peanut allergy. The PEPITES randomized clinical trial. JAMA 2019. pmid:30794314 PubMed
  18. Greenhawt M, Sindhet SB, Wang J, et al. Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy. N Engl J Med 2023; 388: 1755-1766. pmid:37163622 PubMed
  19. Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med 2024. pmid:38407394 PubMed
Annonse
Annonse